The data to be presented at the SIRS Conference will include results of a Phase 2 study for ALKS 3831, the layouts for the ongoing ALKS 3831 clinical studies, which include a pivotal Phase 3 study, and data from a long-term study on the benefits of aripiprazole lauroxil.
ALKS 3831 is Alkermes’ proposed investigational, novel, oral atypical antipsychotic drug that was developed to treat schizophrenia. Aripiprazole lauroxil is an extended-release injectable suspension that is being marketed by Alkermes as ARISTADA. It is currently approved in the United States for schizophrenia treatment.
The presentations at the SIRS Conference on ALKS 3831 will include data from a Phase 3 study that looked at the effectiveness and safety of the drug, Phase 2 data that studied effectiveness and safety, as well as patient tolerability, and a second Phase 3 trial that evaluated weight gain in patients taking ALKS 3831. Presentations on ARISTADA will look at the stability of the medication in a 52-week study and its long-term safety and durability.
Alkermes is a leader in innovative medicines that address the unmet needs and challenges of people living with debilitating diseases.
Alerts Sign-up